Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biopharmaceutical company Isotechnika has announced the first sale of voclosporin active pharmaceutical ingredient for commercial use to its partner, Lux Biosciences, a clinical stage biotechnology company.
Subscribe to our email newsletter
Lux Biosciences has licensed the global rights to all ophthalmic indications from Isotechnika and has made an initial payment of $2 million under a commercial supply agreement previously executed between the companies.
Three separate clinical (Luminate) trials are currently investigating Luveniq as a corticosteroid-sparing agent for the treatment of patients with non-infectious uveitis, an autoimmune disease characterized by chronic inflammation of the eye and one of the leading causes of blindness. Lux Biosciences’s plan is to launch Luveniq in 2010, subject to successful completion of the Luminate trials and regulatory approval.
Clemens Kaiser, chief marketing officer of Isotechnika, said: “Our partner, Lux Biosciences, has significantly advanced the clinical development Luveniq for the eventual commercial launch in the treatment of uveitis. This is the first commercial supply of voclosporin to our partner and obviously a significant milestone event for Isotechnika. It is great to see that we are now measuring progress in material sales as well as clinical milestones.”